Targeted therapies for triple negative breast cancer

VastCon is developing targeted therapies for hard to treat metastatic cancers such triple negative breast cancer (TNBC) through its wholly owned subsidiary, Oncodrex (www.oncodrex.com). 

The company has identified unique molecular signatures in metastatic TNBC and is developing small molecules as drug candidates against this signature. This unique molecular signature also has allowed the company to develop a companion diagnostic to select responders to its TNBC drug candidate, an attractive component in a drug development program.